Readisorb is highly studied and has been published in over 11 studies
It has been extensively studied in pre-clinical and clinical contexts for its photoprotective properties, with research demonstrating dose-dependent increases in eumelanin production in keratinocyte and melanocyte co-culture models
Evogliptin, a novel dipeptidyl peptidase 4 (DPP4) inhibitor, is more commonly used in clinical practice for its potent glucose-lowering effects without any serious adverse events, especially on glycemic variability in patients with T2DM [13]
Safety, efficacy, and appropriate handling in humans or animals have not been established
You can have bone density loss and muscle loss with weight loss with any modality, says Kunal Shah , MD, is an assistant professor in the division of endocrinology at the Rutgers Robert Wood Johnson Medical Center
There is no cure